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Background
Cytotoxic T lymphocytes (CTL) are thought to play a cen-
tral role in protection against HIV infection. This has been
a major impetus for the design and testing of vaccines
capable of eliciting a broad and vigorous CTL response to
prevent or as a lesser goal, to ameliorate the disease course
and viral transmission.
Methods
A chimeric peptide containing a 12-mer DC binding moi-
ety fused to nonamer D-arginine residues (9dR) was
developed for potential DC-specific siRNA delivery in
vivo.
Results
Targeted silencing of SOCS-1 in human DCs a) enhanced
their cytokine responses to LPS and stimulated a strong
mixed lymphocyte reaction in vitro, b) elicited a strong
primary in vitro response to HLA-A2-restricted Melan-A/
MART-1 and HIV Gag SL9 epitope in naïve CD8+ T cells
from healthy donors and c) increased the HIV gag-specific
cytokine response in CD8 T cells from seropositive sub-
jects. More importantly, in HLA-A2 transgenic NOD/
SCID-iL2rγ-/- mice reconstituted with CD34 HSC from
HLA-A2 donors, injection of SOCS-1 silenced DCs pulsed
with HIV A2-restricted gag peptides, but not the irrelevant
flu peptide, gave rise to a robust HIV specific CD8 T cell
response which protected effectively against lethal chal-
lenge with recombinant HIV Gag-vaccinia.
Conclusion
These results demonstrate the feasibility of using targeted
RNAi to manipulate DC as a strategy to boost the immu-
nogenicity of CTL epitope vaccines for HIV and attest to
the value of the novel HLA-transgenic humanized mouse
model in dissecting the protective role of HIV specific
CD8 T cells restricted by specific HLA- alleles.
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